Předléčebné stanovení radiosenzitivity nádorů hlavy a krku

HORÁKOVÁ, Zuzana, Hana BINKOVÁ, M. FALK, Michal MASAŘÍK, I. FALKOVÁ, D. DEPEŠ, J. GUMULEC, A. BAČÍKOVÁ, E. PAGÁČOVÁ, Rom KOSTŘICA, Alena RAFAJOVÁ, Tereza HLOŽKOVÁ and Břetislav GÁL. Předléčebné stanovení radiosenzitivity nádorů hlavy a krku (Prior to treatment radiosensitivity in head and neck cancer). In 78. kongres České společnosti otorinolaryngologie a chirurgie hlavy a krku ČLS JEP. 2016.

Basic information

• Original name: Předléčebné stanovení radiosenzitivity nádorů hlavy a krku
• Name (in English): Prior to treatment radiosensitivity in head and neck cancer
• Authors: HORÁKOVÁ, Zuzana (203 Czech Republic, guarantor, belonging to the institution), Hana BINKOVÁ (203 Czech Republic, belonging to the institution), M. FALK (203 Czech Republic), Michal MASAŘÍK (203 Czech Republic, belonging to the institution), I. FALKOVÁ (203 Czech Republic), D. DEPEŠ (203 Czech Republic), J. GUMULEC (203 Czech Republic), A. BAČÍKOVÁ (203 Czech Republic), E. PAGÁČOVÁ (203 Czech Republic), Rom KOSTŘICA (203 Czech Republic, belonging to the institution), Alena RAFAJOVÁ (203 Czech Republic, belonging to the institution), Tereza HLOŽKOVÁ (203 Czech Republic, belonging to the institution) and Břetislav GÁL (203 Czech Republic, belonging to the institution).
• Edition: 78. kongres České společnosti otorinolaryngologie a chirurgie hlavy a krku ČLS JEP, 2016.

Other information

• Original language: Czech
• Type of outcome: Conference abstract
• Field of Study: 30200 3.2 Clinical medicine
• Country of publisher: Czech Republic
• Confidentiality degree: is not subject to a state or trade secret
• RIV identification code: RIV/00216224:14110/16:00088721
• Organization unit: Faculty of Medicine
• Keywords in English: DNA double strand; flbroblasts and skin flbroblasts
• Tags: EL OK

Abstract

Nádory hlavy a krku jsou charakterizovány svým agresivním chováním s následky těžkého poškození pacienta podmíněné jednak nádorem samotným, jednak v důsledku chirurgické léčby. Možnosti v tomto směru nabízí stále preferovanější nechirurgická léčba- radioterapie, resp. chemoradioterapie. Velká část nádorů, až 60%, není k léčbě radioterapií dostatečně sensitivní. Volba primární léčebné modality je pro výsledek a prognózu pacienta stěžejní. Neexistuje doposud žádný marker charakterizující radiosensitivitu nádoru, který by se stal vodítkem k indikaci primární radioterapie.

Abstract (in English)

Aims: Head and neck tumour are agressively growing and the oncologic treatment often results in mutilation of the patiens and the quality of life impairment. Thus recently the non-surgical treatment (radiotherapy) is vastly prefered. However, more than 50% of the tumours are not radio-sensitive enought. Unfortunately, still any sensitivizy marker for a useful pre treatment radiosensitivity assesment is missing. Methods: On cancer cell lines the DNA damage is assesed; DNA double strand breaks are visualized by immunofluoroscopy, their count, repair dynamic and capacity in real time) Results: cell lines were separated and cultivated from tissue samples taken from patiens prior to treatment) were in vitro irradiated ( 2Gy, 60 Co) and quantified DNA yH2AX/53PBl foci before, immediatly after irradiation (5min.,) and in the course of the next 24 hours. Results obtained on cancer cells, tumour associated flbroblasts and skin fibroblasts of the same patient were compaired. The preliminary results confirmed higher genomic instability in both tomour cell and tumour associated fibroblast in comparison with normal skinfibroblasts. Conclusion The difference in behaviour between both tumour cell lines and normal flbroblasts in vitro condition after experimental irradiation should be supported by father experimental in vitro and in vivo conditions (clinical tumour responce to radiotherapy and other histopathological and clinical tumour parameters should be futher consederd so that the radiosensitivity could be in vitro estimated prior to treatment decision making.

Links

• GA16-12454S, research and development project: Name: Charakterizace a modifikace komplexní odpovědi buněk nádorů hlavy a krku na různá záření - krok kupředu ke kombinované personalizované (radio)terapii

Investor: Czech Science Foundation

• NV16-29835A, research and development project: Name: Molekulárně-genetické markery predikce účinnosti radioterapie u nádorů hlavy a krku